AR and neoplasm: Then arrives an unprecise period of dormancy followed by epigenetic reprogramming processes that will allow PCa metastatic cells to survive and escape therapies, particularly the androgen receptor signaling blockade, thus converting the neoplasm in a castration-resistant cancer, the common final pathway in the clinical evolution of PCa.